Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805

Molecular Cancer Therapeutics

Volumn 9, Issue 7, 2010, Pages 1945-1955

  Baffert, Fabienne ^a   Régnier, Catherine H ^a   De Pover, Alain ^a   Pissot Soldermann, Carole ^a   Tavares, Gisele A ^a   Blasco, Francesca ^a   Brueggen, Josef ^a   Chène, Patrick ^a   Drueckes, Peter ^a   Erdmann, Dirk ^a   Furet, Pascal ^a   Gerspacher, Marc ^a   Lang, Marc ^a   Ledieu, David ^a   Nolan, Lynda ^a   Ruetz, Stephan ^a   Trappe, Joerg ^a   Vangrevelinghe, Eric ^a   Wartmann, Markus ^a   Wyder, Lorenza ^a,b   Hofmann, Francesco ^a   Radimerski, Thomas ^a   more..

^a NOVARTIS PHARMA AG   (Switzerland)

^b ACTELION PHARMACEUTICALS LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; NVP BSK 805; QUINOXALINE; STAT5 PROTEIN; UNCLASSIFIED DRUG; ADENOSINE TRIPHOSPHATE; NVP-BSK805; QUINOXALINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL SPREADING; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG TOLERABILITY; ENZYME INHIBITION; ERYTHROPOIESIS; EXTRAMEDULLARY HEMATOPOIESIS; FEMALE; HUMAN; IC 50; LEUKEMIA CELL; MOUSE; NONHUMAN; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SPLENOMEGALY; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CELL LINE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; GENETICS; K562 CELL LINE; METABOLISM; MUTATION; PATHOLOGY; PHOSPHORYLATION; POLYCYTHEMIA; PROTEIN TERTIARY STRUCTURE; RAT; SCID MOUSE; TUMOR CELL LINE;

ADENOSINE TRIPHOSPHATE; ANIMALS; APOPTOSIS; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; ERYTHROPOIESIS; HUMANS; JANUS KINASE 2; K562 CELLS; MICE; MICE, INBRED BALB C; MICE, SCID; MODELS, MOLECULAR; MOLECULAR STRUCTURE; MUTATION; PHOSPHORYLATION; POLYCYTHEMIA; PROTEIN STRUCTURE, TERTIARY; QUINOXALINES; RATS; SPLENOMEGALY; STAT5 TRANSCRIPTION FACTOR;

EID: 77954619670     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0053     Document Type: Article

References (41)

1. James C, Ugo V, Le Couedic J-P, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-8. (Pubitemid 40663494)
2. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-97.
3. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-90.
4. Thompson JE. JAK protein kinase inhibitors. Drug News Perspect 2005;18:305-10.
5. Mesa RA. Navigating the evolving paradigms in the diagnosis and treatment of myeloproliferative disorders. Hematology 2007;2007:355-62.
6. Tefferi A, Gilliland DG. JAK2 in myeloproliferative disorders is not just another kinase. Cell Cycle 2005;4:4053-6.
7. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007;356:459-68.
8. Bercovich D, Ganmore I, Scott LM, et al. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet 2008;372:1484-92.
9. Kearney L, Gonzalez De Castro D, Yeung J, et al. Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia. Blood 2009;113:646-8.
10. Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006;3:e270.
11. Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006;108:3472-6.
12. Weniger MA, Melzner I, Menz CK, et al. Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation. Oncogene 2006;25:2679-84.
13. Lacronique V, Boureux A, Della Valle V, et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 1997;278:1309-12.
14. Verstovsek S. Therapeutic potential of Janus-activated kinase-2 inhibitors for the management of myelofibrosis. Clin Cancer Res 2010;16:1988-96.
15. Pissot-Soldermann C, Gerspacher M, Furet P, et al. Discovery and SAR of potent, orally available 2,8-diaryl-quinoxalines as a new class of JAK2 inhibitors. Bioorg Med Chem Lett 2010;20:2609-13.
16. Lucet IS, Fantino E, Styles M, et al. The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. Blood 2006;107:176-83.
17. Shannon K, Van Etten RA. JAKing up hematopoietic proliferation. Cancer Cell 2005;7:291-3.
18. Stepkowski SM, Kirken RA. Janus tyrosine kinases and signal transducers and activators of transcription regulate critical functions of T cells in allograft rejection and transplantation tolerance. Transplantation 2006;82:295-303.
19. Levine RL, Pardanani A, Tefferi A, Gilliland DG. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 2007;7:673-83.
20. Erdmann D, Allard B, Bohn J, et al. Kinetic study of human full-length wild-type JAK2 and V617F mutant proteins. Open Enzyme Inhib J 2008;1:80-4.
21. Thompson JE, Cubbon RM, Cummings RT, et al. Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor. Bioorg Med Chem Lett 2002;12:1219-23.
22. Lu X, Levine R, Tong W, et al. Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proc Natl Acad Sci U S A 2005;102:18962-7.
23. Pardanani A, Hood J, Lasho T, et al. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L//K mutations. Leukemia 2007;21:1658-68.
24. Quentmeier H, MacLeod RAF, Zaborski M, Drexler HG. JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders. Leukemia 2006;20:471-6. (Pubitemid 43291746)
25. Walters DK, Mercher T, Gu T-L, et al. Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell 2006;10:65-75.
26. Gozgit JM, Bebernitz G, Patil P, et al. Effects of the JAK2 inhibitor, AZ960, on Pim/BAD/BCL-xL survival signaling in the human JAK2 V617F cell line SET-2. J Biol Chem 2008;283:32334-43.
27. Muntzel M, Hannedouche T, Lacour B, Drueke T. Effect of erythropoietin on hematocrit and blood pressure in normotensive and hypertensive rats. J Am Soc Nephrol 1992;3:182-7.
28. Woo S, Krzyzanski W, Jusko WJ. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after intravenous and subcutaneous administration in rats. J Pharmacol Exp Ther 2006;319:1297-306.
29. Shikama Y, Ishibashi T, Kimura H, Kawaguchi M, Uchida T, Maruyama Y. Transient effect of erythropoietin on thrombocytopoiesis in vivo in mice. Exp Hematol 1992;20:216-22.
30. Loo M, Beguin Y. The effect of recombinant human erythropoietin on platelet counts is strongly modulated by the adequacy of iron supply. Blood 1999;93:3286-93. (Pubitemid 29220895)
31. Vannucchi AM, Bianchi L, Cellai C, et al. Accentuated response to phenylhydrazine and erythropoietin in mice genetically impaired for their GATA-1 expression (GATA-1low mice). Blood 2001;97:3040-50.
32. Richmond TD, Chohan M, Barber DL. Turning cells red: signal transduction mediated by erythropoietin. Trends Cell Biol 2005;15:146-55.
33. Vannucchi AM. How do JAK2-inhibitors work in myelofibrosis: an alternative hypothesis. Leuk Res 2009;33:1581-3.
34. Mesa R, Gale RP. Hypothesis: how do JAK2-inhibitors work in myelofibrosis. Leuk Res 2009;33:1156-7.
35. Mathur A, Mo J-R, Kraus M, et al. An inhibitor of Janus kinase 2 prevents polycythemia in mice. Biochem Pharmacol 2009;78:382-9.
36. Liberati T, Sansone S, Feuston M. Hematology and clinical chemistry values in pregnant Wistar Hannover rats compared with nonmated controls. Vet Clin Pathol 2004;33:68-73.
37. McDonald T, Sullivan P. Megakaryocytic and erythrocytic cell lines share a common precursor cell. Exp Hematol 1993;21:1316-20. (Pubitemid 24222994)
38. Parganas E, Wang D, Stravopodis D, et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell 1998;93:385-95.
39. Tiedt R, Hao-Shen H, Sobas MA, et al. Ratio of mutant JAK2-617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood 2008;111:3931-40.
40. Saharinen P, Vihinen M, Silvennoinen O. Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain. Mol Biol Cell 2003;14:1448-59.
41. Delhommeau F, Dupont S, Valle VD, et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009;360:2289-301.